KM3D Multicenter Cancer Consortium: Predicting Patient Response Using 3D Cell Culture Models

Overview

About this study

This study will assess the ability of the Pathos platform to predict which patients will respond to certain colorectal cancer drug treatments. To demonstrate that for patients with advanced colorectal cancer, prediction scores based on in vitro tumor organoid drug response are positively associated with the rate of first line response.    

To demonstrate that for patients with advanced colorectal cancer, prediction scores based on in vitro tumor organoid drug response are positively associated with progression free survival.

To demonstrate that for patients with advanced colorectal cancer who meet the endpoint of first line response, prediction scores based on in vitro tumor organoid drug response are positively associated with duration of first line response.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- A demonstrated primary solid cancer for which it is medically indicated and planned to
be surgically resected, biopsied, or drained (via malignant pleural effusion).

- The ability to ship the tissue sample within 24 hours of removal from the patient.

- Signed and dated consent to giving tissue as well as allowing for de-identified
medical history information regarding administered treatments and treatment outcomes
to be shared.

- over 18 years of age

Exclusion Criteria:

- Presence of a condition(s) or diagnosis, either physical or psychological, or physical
exam finding that precludes participation in the opinion of the Investigator.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 2/9/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

David Larson, M.D., M.B.A.

Contact us for the latest status

Contact information:

Yulia Potter Nichols

(507) 422-9029

PotterNichols.Yulia@mayo.edu

More information

Publications

Publications are currently not available